Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Case 61% Improvement Relative Risk HCQ for COVID-19  Satti et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 80 patients in Qatar Fewer cases with HCQ (p=0.041) c19hcq.org Satti et al., Cureus, April 2022 Favors HCQ Favors control

Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar

Satti et al., Cureus, doi:10.7759/cureus.24382
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Retrospective 80 consecutive pregnant patients with autoimmune rheumatic diseases in Qatar, showing lower risk of COVID-19 cases with HCQ prophylaxis.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of case, 61.5% lower, RR 0.39, p = 0.04, treatment 10 of 63 (15.9%), control 7 of 17 (41.2%), NNT 4.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Satti et al., 22 Apr 2022, retrospective, Qatar, peer-reviewed, 6 authors. Contact: salemadi@hamad.qa.
This PaperHCQAll
Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar
Eman Satti, Monika Ostensen, Soha Darrgham, Nawal Hadwan, Samar Hadeel Ashour, Samar Al Emadi
Cureus, doi:10.7759/cureus.24382
Objective: Pregnant women with autoimmune rheumatic diseases are considered to have a high risk of obstetric complications with the emergence of the Coronavirus disease (COVID-19) pandemic. Therefore, we aimed to assess the impact of COVID-19 on this high-risk group. Methods: This cross-sectional cohort study (March to December 2020) was conducted at the largest tertiary center in Qatar (Hamad Medical Corporation). Eighty consecutive patients following up at the center during pregnancy were surveyed through telephonic interviews. Data on COVID-19 and pregnancy outcomes were extracted from electronic hospital records. Results: Eighty pregnant women with autoimmune rheumatic diseases were included. Among them, 17 (21.3%) (95% confidence interval [CI]: 12.9-31.8%) were diagnosed with COVID-19, five were hospitalized, and only one required intensive care unit admission. The proportion of adverse obstetric outcomes in the cohort was 29.5% (n = 23; 95% CI: 19.7-40.9%). Prematurity (n = 14; 19.4%) and caesarean section (n = 30; 41.1%) were the most prevalent adverse events. There was no statistical difference in adverse pregnancy outcomes between women with and without COVID-19. Conclusion: COVID-19 did not affect pregnancy outcomes in women with autoimmune rheumatic diseases.
Additional Information Disclosures
References
Allotey, Stallings, Bonet, Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis, BMJ, doi:10.1136/bmj.m3320
Arora, Isenberg, Castrejon, Measures of adult systemic lupus erythematosus: disease activity and damage, Arthritis Care Res, doi:10.1002/acr.24221
Barbhaiya, Stamm, Vitone, Pregnancy and rheumatic disease: experience at a single center in New York City during the COVID-19 pandemic, Arthritis Care Res, doi:10.1002/acr.24547
Bermas, Gianfrancesco, Tanner, COVID-19 in pregnant women with rheumatic disease: data from the COVID-19 global rheumatology alliance, J Rheumatol, doi:10.3899/jrheum.210480
Boyadzhieva, Stoilov, Stoilov, Coronavirus disease 2019 (COVID-19) during pregnancy in patients with rheumatic diseases, Rheumatol Int, doi:10.1007/s00296-020-04698-y
Gianfrancesco, Hyrich, Al-Adely, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physicianreported registry, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217871
Katz, Bateman, Kjaer, The Society for Obstetric Anesthesia and Perinatology Coronavirus Disease 2019 Registry: The Society for Obstetric Anesthesia and Perinatology (SOAP) COVID-19 Registry: an analysis of outcomes among pregnant women delivering during the initial SARS-CoV-2 outbreak in the United States, Anesth Analg, doi:10.1213/ANE.0000000000005592
Lu, Li, Liu, Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217460
Mikuls, Johnson, Fraenkel, American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 3, Arthritis Rheumatol, doi:10.1002/art.41596
Nakamura, Kotani, Hiramatsu, Simplified disease activity index and clinical disease activity index before and during pregnancy correlate with those at postpartum in patients with rheumatoid arthritis, Mod Rheumatol, doi:10.1080/14397595.2020.1829342
Petri, Kim, Kalunian, Combined oral contraceptives in women with systemic lupus erythematosus, N Engl J Med, doi:10.1056/NEJMoa051135
Prabhu, Cagino, Matthews, Pregnancy and postpartum outcomes in a universally tested population for SARS-CoV-2 in New York City: a prospective cohort study, BJOG, doi:10.1111/1471-0528.16403
Silva, Boyd, Wallwork, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217888
Yang, Mei, Zheng, Pregnant women with COVID-19 and risk of adverse birth outcomes and maternal-fetal vertical transmission: a population-based cohort study in Wuhan, China, BMC Med, doi:10.1186/s12916-020-01798-1
Østensen, Andreoli, Brucato, State of the art: reproduction and pregnancy in rheumatic diseases, Autoimmun Rev, doi:10.1016/j.autrev.2014.12.011
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit